Epigallocatechin‐3‐gallate promotes wound healing response in diabetic mice by activating keratinocytes and promoting re‐epithelialization

Abstract Type 2 diabetes (T2D) is a metabolic disorder that causes numerous complications including impaired wound healing and poses a significant challenge for the management of diabetic patients. Epigallocatechin‐3‐gallate (EGCG) is a natural polyphenol that exhibits anti‐inflammatory and anti‐oxidative benefits in skin wounds, however, the direct effect of EGCG on epidermal keratinocytes, the primary cells required for re‐epithelialization in wound healing remains unknown. Our study aims to examine the underlying mechanisms of EGCG's ability to promote re‐epithelialization and wound healing in T2D‐induced wounds. Murine models of wound healing in T2D were established via feeding high‐fat high‐fructose diet (HFFD) and the creation of full‐thickness wounds. Mice were administered daily with EGCG or vehicle to examine the wound healing response and underlying molecular mechanisms of EGCG's protective effects. Systemic administration of EGCG in T2D mice robustly accelerated the wound healing response following injury. EGCG induced nuclear translocation of nuclear factor erythroid 2‐related factor 2 (NRF2) and promoted cytokeratin 16 (K16) expression to activate epidermal keratinocytes and robustly promoted re‐epithelialization of wounds in diabetic mice. Further, EGCG demonstrated high binding affinity with Kelch‐like ECH‐associated protein 1 (KEAP1), thereby inhibiting KEAP1‐mediated degradation of NRF2. Our findings provide important evidence that EGCG accelerates the wound healing response in diabetic mice by activating epidermal keratinocytes, thereby promoting re‐epithelialization of wounds via K16/NRF2/KEAP1 signaling axis. These mechanistic insights into the protective effects of EGCG further suggest its therapeutic potential as a promising drug for treating chronic wounds in T2D.